Can DANNALAB Support Batch Release, Stability Studies, and Patent Analysis?

Updated

Yes. DANNALAB is built around exactly these three use cases: cGMP-compliant XRPD and SAXS testing for pharmaceutical CMC, with QA-approved CoAs for batch release, ICH-compliant method validation for stability and forced-degradation work, and technical comparison of XRPD/SAXS data against patent claims and specifications. Turnaround as fast as 24–48 hours is listed as available for time-sensitive projects. The main condition to check before committing is fit: which technique (XRPD vs. SAXS) matches your sample type, and whether your specific method falls under the cGMP documentation scope offered.

Batch Release and Quality Control

XRPD is positioned as part of release packages for small-molecule drugs, covering polymorphism, crystallinity, and identity of APIs and formulations. The relevant commitments from the site:

  • QA-approved CoA issued with results, described as batch-release ready.
  • cGMP accredited since 2014, with USP <941>, Ph.Eur <2.9.33>, and 21 CFR Part 11 traceable data cited as the operating framework.
  • 24–48 hour turnaround available — useful when a release decision is holding up a shipment or a deviation investigation.

One practical constraint worth knowing: pharmaceuticals imported into the EU require GMP testing in an EU laboratory under Directive 2001/83/EC. If your batch release depends on EU import testing, confirm with DANNALAB that the specific test and documentation meet that requirement before you plan around it.

Stability Studies and Method Validation

For stability and forced-degradation work, the site lists:

  • Stability and forced-degradation studies under the SAXS/biopharmaceuticals offering, including aggregation and oligomerisation detection — relevant for proteins, peptides, and antibodies in native solution.
  • ICH-compliant method validation with LOD/LOQ determination in the 0.17–0.5% wt range for XRPD, plus rapid feasibility assessment.

The LOD/LOQ figures matter for a concrete reason: if you need to detect a low-level polymorphic impurity or a small crystalline fraction in a mostly amorphous formulation, a limit of detection around 0.17–0.5% wt sets the floor on what a stability trend can actually show. If your specification sits below that range, raise it early — method development may be needed rather than a standard validated method.

Choosing the right technique before you brief the lab

Your sample / question Technique indicated on the site
API or formulation polymorphism, crystallinity, identity XRPD
Protein, peptide, or antibody structure in native solution; biosimilar comparability; aggregation SAXS
LNP, liposome, nanoemulsion structure; mRNA-LNP assembly; lipid phase SAXS (combined SAXS/WAXS for lipid carriers)
Peptide solid state: amorphicity, crystallinity, polymorph and salt form XRPD
Nanoparticle size distribution and inner structure SAXS

Getting this wrong is the most common way a quote cycle stalls, so state your sample matrix and the decision the data must support in your first inquiry.

Patent Analysis

DANNALAB offers technical analysis of XRPD and SAXS data against patent claims and specifications. In practice this means you bring the patent language and the measured pattern or scattering profile, and the comparison is documented technically. Two things to settle up front:

  1. Scope — confirm whether you need a comparison report or something intended to support a formal opinion; the site describes technical analysis, not legal advice.
  2. Data provenance — for a comparison to hold up, the underlying measurement should come from a validated method with traceable data (21 CFR Part 11 is cited). If you are comparing against someone else's published pattern, say so, because instrument and sample-prep differences affect peak positions and intensities.

What to Confirm Before You Commit

  • Turnaround: 24–48 hours is described as available, not standard — confirm the timeline for your specific assay when requesting a quote.
  • Pricing: the site invites a "Technical Quote or Price List" request but publishes no rates, so budget only after you have the quote in hand.
  • Method coverage: cGMP documentation is noted as available for selected SAXS methods (drug delivery systems), so verify your method is in scope if you need a regulated submission package.
  • Sample type fit: peptide work spans both solid-state (XRPD) and solution-state (SAXS), so specify which you need.

The fastest path is to request a technical quote with your sample type, the CMC stage (release, stability, or patent comparison), and your deadline — that lets DANNALAB confirm technique, documentation level, and whether the 24–48 hour window applies to your assay.